Welcome to our dedicated page for AngioDynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on AngioDynamics stock.
Founded in 1988 in Queensbury, N.Y., U.S., AngioDynamics, Inc. (NASDAQ: ANGO) is a leading provider of innovative medical devices that serve interventional radiologists, nephrologists, and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. The company's product portfolio includes market-leading systems such as the NanoKnife® system, radiofrequency ablation devices, and a variety of vascular access, angiographic, dialysis, angioplasty, and embolization products.
AngioDynamics has a strong track record of developing and bringing new technologies to market, maintaining a dynamic presence in the high-growth medical device industry. Recently, the company reported net sales of $78.7 million for the first quarter of fiscal year 2024, including a 13.3% increase in Med Tech net sales driven by the NanoKnife platform. AngioDynamics also completed the sale of its Dialysis and BioSentry Biopsy Tract Sealant System businesses, significantly enhancing its financial flexibility.
In addition to financial growth, AngioDynamics continues to innovate with significant developments such as the APEX-AV study, aimed at evaluating the safety and efficacy of the AlphaVac F1885 System for treating acute pulmonary embolism. The company’s AlphaVac F1885 System has recently received FDA clearance for the treatment of pulmonary embolism, a significant milestone that expands its indication in critical medical scenarios.
With ongoing plans to transition to a fully outsourced manufacturing model and recent divestitures to streamline its portfolio, AngioDynamics is well-positioned to focus on its core strengths and drive long-term profitability. The company's net sales are projected to be between $328 to $333 million for fiscal year 2024, with an anticipated improved gross margin and reduced adjusted loss per share.
AngioDynamics (NASDAQ:ANGO), a leader in minimally invasive medical devices, announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the Needham Virtual Healthcare Conference on April 12, 2021, at 8:45 a.m. ET. Investors can access the live webcast through AngioDynamics’ website, where a replay will also be available post-event. The company specializes in products for vascular access, peripheral vascular disease, and oncology, including ablation systems and vascular access products.
AngioDynamics (NASDAQ: ANGO) reported its third-quarter fiscal 2021 financial results, showing a 2% year-over-year revenue growth to $71.2 million, despite COVID-19 challenges. Vascular Interventions and Therapies sales increased by 8.8% to $33.3 million. However, Oncology sales dropped by 10.1% to $13.1 million. The company recorded a net loss of $3.5 million, improving from a $5.7 million loss last year. The gross margin declined to 54.1% due to Auryon start-up costs and COVID-related impacts. Adjusted guidance for FY2021 is now $285-$288 million in sales.
AngioDynamics (NASDAQ: ANGO) announced that CEO Jim Clemmer and CFO Stephen Trowbridge will take part in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum. The event is scheduled for 10:00 a.m. ET on March 24, 2021. Investors can access a live webcast through the company’s website, with replay availability post-event. AngioDynamics specializes in minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, offering a range of leading products.
AngioDynamics, Inc. (NASDAQ: ANGO) announces participation in a virtual fireside chat at the 31st Annual Oppenheimer Healthcare Conference. Scheduled for March 16, 2021, at 9:20 a.m. ET, CEO Jim Clemmer and CFO Stephen Trowbridge will discuss company insights. A live webcast will be available through the Company’s website, with replay options post-event. AngioDynamics specializes in innovative, minimally invasive medical devices for vascular access, oncology, and peripheral vascular disease, focusing on diverse product lines that enhance patient care.
AngioDynamics, Inc. (NASDAQ: ANGO) will report its financial results for Q3 FY2021 on March 30, 2021, before the market opens. Management will host a conference call at 8:00 a.m. ET to discuss these results. Interested participants can join by calling 1-877-407-0784 domestically or +1-201-689-8560 internationally, using passcode 13717367. The call will also be available via webcast on the AngioDynamics website, with a replay accessible shortly after the call concludes.
AngioDynamics, a leader in minimally invasive medical devices, has announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the Barclays Virtual Global Healthcare Conference on March 9, 2021, at 8:00 a.m. ET. Investors can access a live webcast of the presentation through the Company’s website, with a replay available later. AngioDynamics specializes in devices for vascular access, peripheral vascular disease, and oncology, offering a range of products including ablation systems and thrombolytic products.
AngioDynamics, Inc. (NASDAQ: ANGO) has appointed Richard C. Rosenzweig as Senior Vice President and General Counsel effective January 31, 2021. He succeeds Stephen Trowbridge, who will continue as Chief Financial Officer. Additionally, Juan Carlos Serna has been promoted to Senior Vice President of Scientific and Clinical Affairs, overseeing key teams for advancing scientific research and patient access. Both appointments are seen as strategic moves to enhance leadership and drive growth in AngioDynamics' medical technologies.
AngioDynamics reported Q2 fiscal 2021 results showing net sales of $72.8 million, up 4% year-over-year despite COVID-19 disruptions. Growth in Vascular Interventions and Therapies was driven by AngioVac sales, which rose 8.8%. However, net loss increased to $4.3 million or $0.11 per share. Gross margin declined to 55.2%, largely due to COVID-related operating costs. For the six months ending November 30, total sales were $143 million, up 5.1%. The company maintains a fiscal 2021 sales guidance of $278 to $284 million.
AngioDynamics, Inc. (NASDAQ: ANGO) has announced that Jim Clemmer, President and CEO, along with Stephen Trowbridge, Executive VP and CFO, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference at 2:50 p.m. ET on January 14, 2021.
A live webcast will be available in the 'Investors' section of AngioDynamics' website, with a replay accessible after the event. AngioDynamics specializes in innovative, minimally invasive medical devices focused on vascular access, peripheral vascular disease, and oncology.
AngioDynamics, Inc. (NASDAQ: ANGO) announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the 23rd Annual Needham Virtual Growth Conference on January 11, 2021, at 1:15 p.m. ET. The presentation will be streamed live on the company's website, with a replay available afterward. AngioDynamics specializes in minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, featuring a diverse range of products including ablation and vascular access systems.
FAQ
What is the current stock price of AngioDynamics (ANGO)?
What is the market cap of AngioDynamics (ANGO)?
What does AngioDynamics, Inc. specialize in?
What are some recent achievements of AngioDynamics, Inc.?
What is the AlphaVac F1885 System?
What financial performance did AngioDynamics report for the first quarter of fiscal year 2024?
What are AngioDynamics' future plans for manufacturing?
Where does AngioDynamics generate the majority of its revenue?
What is the NanoKnife® system?
How does AngioDynamics plan to enhance its focus on core strengths?
What is the APEX-AV study?
How does AngioDynamics contribute to the medical device industry?
